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Introclrrc~tion
In this brief communication, we describe the existence of a pulmonary polyamine uptake system. We discuss the presence o f similar uptake systems in a numbcr o f other cell typcs. in particular certain tumour cells. Finally, we discuss the possible therapeutic exploitation of this pulmonary polyaminc uptake system. in particular, in relation to the design of novel anticancer agents and better radioprotective agents and finally its possible exploitation in antiprotozoal chemot herapy.
71ic cli.scw\rry of u piilmonury polyumine irptuke system In the course o f studies in one of our laboratories on the mechanism of pulmonary toxicity of the herbicide paraquat ( I , If-dimcthyl-4,4'-bipyridilium), we noted that a critical component of the mechanism was the initial accumulation o f paraquat in the lung [ 11. This uptake was shown to occur by an active energy-dependent transport system [2] . Endogenous polyamines (putrescine, spermidine and spermine) appeared t o be the natural substrates for this uptake system 131. T h e polyamines were also accumulated in the lung by an active energy-dependent uptake system [3, 41, and they competitively inhibited the accumulation of paraquat in both lung slices and isolated alveolar epithelial type I1 cells. Extensive structure-activity relationships have been carried out to determine the key features o f molecules necessary t o inhibit pulmonary polyamine accumulation IS]. This work was aimed both at characterization of the polyamine uptake system a s well as with a view t o designing potential antidotes for paraquat toxicity. Some key structural characteristics of the pulmonary polyamine uptake system, which have been revealed from these studies are that in order to be a good inhibitor a molecule requires: ( u ) one or, preferably, two charged nitrogen-containing cationic groups; ( h ) a distance equivalent t o 4-7 methylene units between the cationic centres. ( c ) no carboxyl groups adjacent t o a cationic centre; ( d ) steric factors o r ionic interactions which may result in hindered access to the cationic-binding site [S]. In more recent studies, we have also shown that disulphides such as Ahhrcviations used: MGBG. methylglyoxal-bis(guany1-hydrazone): DFMO. oi.-a-difluoromethylornithine; S-ABEP. S-214-uminohutylnmino)ethyl phosphorothioate: S-AHEP, S-2( 7-aminohcpty1amino)ethyl phosphorothioate. cystamine may also be accumulated by this system and subsequently may serve an important role as antioxidants in the lung 161. The lung is a heterogeneous organ comprising over 40 cell types, but recent studies have suggested that the pulmonary polyamine uptake system resides primarily in alveolar type I and I1 cells and possibly also in Clara cells 17. 81.
Polyumine irptuke sy.stems in tiitnow cells und their exploitution j b r cancer chemotherupy
During the course of our studies on the characterization of the pulmonary polyamine uptake system, we noted that the antitumour drug. methylglyoxal-bis(guany1hydrazone) (MGBG) IY], a structural analogue of spermidinc. was a potent inhihitor of the pulmonary polyamine uptakc system 151. In further studies, we observed that MGBG was also a substrate for the pulmonary polyamine uptake system 1101. A study of the literature revealed that the uptake of MGBG into various cell typcs including mouse ascites L 12 I0 tumour cells, HeLa, rabbit reticulocytes. non-mammalian reticulocytcs 11 1 I, Ehrlich ascites I 121, and cultured human lymphocytic leukaemic cells [ 131. had been documented and characterized to varying extents. It was apparent to us that there were marked similarities between these documented uptake systems for MGBG and the pulmonary polyamine uptake system. Over the last few years, polyamine uptake An intriguing feature of the polyamine uptake system which merits particular note is that it may be dramatically increased by pretreatment with Dl.-a-difluoromethylornithine (DFMO). D F M O is a specific enzyme-activated irreversible inhibitor of ornithine decarboxylase, the initial and often rate-limiting step in polyamine biosynthcsis I 1 XI.
This inhibition leads to a marked decrease in intracellular polyamines, as a result of which the cell tries t o compensate by stimulating the uptake of extracellular polyamines. Using DFMO pretreatment, it has been shown that cells may concentrate MGBG intracellularly resulting in a greater than 1000-fold intracellular t o extracellular concentration [ 13 I.
We believe that this marked intracellular accumulation of polyamine-related structures may be exploitable in cancer chemotherapy.
Clcarly, structural analogues of the natural polyamines, such as MGBG. can be selectively concentrated in tumour cells. In addition, structural modification of polyamines, such as substitution at the central nitrogen of spermidine with cytotoxic compounds, which in turn d o not interfere with the VOl. 18 BIOCHEMICAL SOCIETY TRANSACTIONS transport of the polyamines [ 191 may be concentrated intracellularly in high cytotoxic concentrations in tumour cells possessing the polyamine uptake system. Such chemicals should be selectively toxic to those cells possessing the uptake system. Two other features of these molecules will add to their selectivity. First, the linkage with the polyamines will target the cytotoxic moiety directly to the DNA, so enhancing its localization in close proximity to the key target macromolecule, i.e. DNA [20] . The other key feature relates to the pharmacokinetics and the mode of administration of these agents. Problems have arisen with MGBG owing to unacceptable host toxicity, although it showed extremely good therapeutic responses in early clinical trials [21] . We suggest that this toxicity may be largely due to the administration of large bolus injections rather than slow infusions of MGBG. A slow infusion of MGBG or related cytotoxic substance at concentrations, which are near their K , for the uptake system into tumour cells, should lead to a selective accumulation in the tumour cells. The patient may have been previously primed with DFMO if this results in a selective depletion of polyamines in the tumour cells compared with critical normal cell populations. Such infusions should obviate unnecessary toxicity caused by peak concentrations reached in different tissues. Such continuous intravenous infusions have been shown to lower the toxicity of a number of chemicals, including the pulmonary toxicity of bleomycin as well as enhancing its antitumour activity 1221.
Potential exploitation of polyumine uptake system in targeting radioprot ector. 5 We have recently found that the radioprotective compound WR272 1 [ S-2( 3-aminopropylamino)ethyl phosphorothioate], can act as a substrate for the uptake system [23] . However, the separation of the nitrogen atoms in WR272 1 by three methylene groups suggested that this molecule would be a relatively poor substrate. The ability of a series of S-2( aminoalkylamino)ethyl phosphorothioates to inhibit competitively the uptake of putrescine into the lung was therefore measured and used as an indirect measure of the ability of the radioprotectors to be accumulated into lung. The compounds used were WR272 1; S-2(4-aminobuty1amino)ethyl phosphorothioate (S-ABEP) and S-2( 7-aminoheptylamino)ethyl phosphorothioate (S-AHEP) [23] . Their inhibitory potency increased as the number of methylene groups between the nitrogen atoms increased. These compounds inhibited putrescine accumulation competitively, supporting the suggestion that they are accumulated by the same uptake system. WR272 1 is rapidly dephosphorylated by alkaline phosphatase to form the free thiol N-2-mercaptoethyl-1,3-diaminopropane [24] . Such dephosphorylated radioprotectors may then be oxidized to the disulphide in the absence of dithiothreitol (DTT) [23] , by analogy with cystamine [6] . The disulphide may then be accumulated in a similar manner to that described for the uptake of cystamine. Our results suggested that the transport receptor in the lung recognized the diamine structure in either its free thiol or disulphide form, although chemicals act as more effective ligands in a disulphide form probably as a result of the greater separation between the nitrogens [23] .
These results, together with a greater understanding of the structural requirements for transport by this uptake system, suggest it may be possible to target a wide variety of chemicals to the alveolar type I and type 11 cells, and Clara cells of the lung [7, 81. It is clear that by altering the number of methylene groups separating the amine groups in the substrate, it is possible to alter the affinity of the chemical for the uptake process. It seems reasonable to argue that S-ABEP and S-AHEP may be more effectively accumulated by the lung than WR2721, thereby providing a more targeted and consequently more effective radioprotection [23] . Again we suggest that to optimize the therapeutic benefit of the polyamine uptake system, the radioprotector should be infused slowly at concentrations approximating the K , of the uptake system.
The lung is not the only organ that has the ability to accumulate polyamines. Theoretically, it should be possible to target sulphur-containing chemicals to other cell types with the uptake system so as to alter their thiol status and thereby protect these cells from oxidative stress.
Utilization of the icptake system in antiprotozoul theruliv
Polyamine metabolism has long been recognized as a potential therapeutic target in trypanosomes [ 251. DFMO has been shown to cure mice infected with a virulent strain of Trypanosoma hnrcei hrircei [25] . DFMO has been used in combination with bleomycin, an anticancer agent with a complicated glycopeptide structure with a number of polyamines attached, so it may possibly utilize the polyamine uptake system. This combination has been shown to be synergistic in treating mice infected with 7; hrircei hrircei, but the effect can be reversed by co-administration of polyamines [26, 271. It is also worthy o f note that a number of compounds used in antimalarial therapy such as primaquine, chloroquine and pentamidine are structurally related to polyamines and have been shown to block the pulmonary polyamine uptake system [28] .
In summary, we have described a pulmonary polyamine uptake system which has marked similarities to a polyamine uptake system present in a number of different cell types, in particular, certain tumour cells. We have described how this uptake system may be exploited to design novel cytotoxic cancer chemotherapeutic agents, as well as designing more efficacious radioprotective agents. The ability to direct a pharmacological agent to its biological target in order to reduce its side-effects while increasing its efficacy has been a medicinal chemist's dream for a long time (and still is). Many different approaches have concentrated on designing complex delivery systems such as mammalian cells, liposomes, liposomes incorporating antibodies, and synthetic polymers (nanoparticles) [ I ] . The function of these delivery systems is to neutralize and protect the native drug in the systemic circulation and eventually to guide it towards the target organ.
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This presentation deals with chemical approaches in which the pharmacological agent is circulating and distributing freely through the whole organism in an inactive form. Through the action of an enzyme (see below) this inactive compound will be transformed into the active drug in the vicinity o f the desired macromolecular target. Depending on the activation mechanism, the following classification is proposed: carriers, pro-drugs, and bioprecursors. In this classification. a carrier is a derivative which takes advantage of a specific transport system, e.g. the peptide portage system in bacteria. A pro-drug relies on a serendipitous enzyme for the activation process, while a bioprecursor enters a metabolic chain at one or two steps before the enzyme it has to inhibit. To illustrate the different concepts, some examples in the domain of catecholamine metabolism have been selected from the literature and from our own work.
A hruiti-specific currier for dopamitie
Dopamine itself does not cross the blood-brain barrier. Its synthesis. which is deficient in Parkinson's disease, is stimulated by the administration of L-dopa. Although this is a generally well accepted and efficient treatment, direct delivery of dopamine to the brain in a sustained and controllable way would represent a valid and attractive alternative. Bodor & Simpkins [ 2 ] described an amine-carrier system based on a redox reaction of a dihydropyridine to pyridinium salts. In short, the amine (for instance phenethylamine) is coupled via an amide link to N-methyl,l,4-dihydropyridine,3-carboxylate. When administered to an animal by a systemic route this lipophilic conjugate crosses the blood-brain barrier. Oxidation of the dihydropyridine to the pyridinium salt in the central nervous system locks the new Abbreviations used: AADC. aromatic amino acid decarhoxylase;
MFMT. a-monofluoromethyl-p-tyrosine; MFMTrp, a-monofluorometh yltryptophan; MAO, monoamineoxidase. conjugate in the brain; chemical or enzyme-catalysed hydrolysis of the slightly more reactive amide bond will then slowly liberate the amine. When applied to doparnine, with the appropriate adjustments, no increase of dopamine concentration in the brain of rats given the conjugate could be demonstrated. However, there was a marked drop of serum prolactin levels, which is consistent with a stimulation o f dopamine receptors in the anterior pituitary gland.
Dopamine renal-specific pro-drug
Dopamine exerts a vasodilatory function by binding to a specific receptor in the kidney. Such an action is beneficial in renal hypertension as demonstrated by slow intravenous infusion of dopamine. However, the therapeutic window is quite narrow and at higher infusion rates, dopamine activates a-adrenergic receptors resulting in a pressor effect. A dopamine derivative which accumulates specifically and libcratcs dopamine in the kidney would overcome this problem. The kidney has an active uptake system and metabolism of yglutamyl derivatives of amines, amino acids and peptides. This is due to the presence o f a high activity o f y-glutamyl transpeptidase activity in the brush-border cells of the proximal tubules. Wilk et al. [ 31 synthesized y-glutamyldopa and studied its biological and pharmacological effects. They demonstrated that y-glutamyldopa accumulates in the kidney, liberates dopa and, through the action of aromatic amino acid decarboxylase (AADC), generates dopamine locally. For instance, after a dose of 0.5 pmol/kg in rats, the kidney concentration of dopamine was six times higher in animals given the y-glutamyl conjugate than in animals given dopa, and the elevation was of longer duration, in agreement with a slow release as dopamine is metabolized very rapidly. This increase of dopamine is accompanied by a marked increase of renal plasma flow.
Iliial-enzyme activated it1hibitor.s of dopamine syrithesls arid metabolism
If a-methyldopa had been designed with the mechanism of action as understood today in mind, it would be a perfect example of this class of compounds. Instead of being a competitive inhibitor of AADC, as originally believed, amethyldopa is transformed into a-methylnoradrenaline, an a2-agonist, by the combined action of AADC and dopamine-p-hydroxylase. Two examples of designed bioprecursors of enzyme-activated inhibitors have been described reccntly.
